19 citations
,
September 2013 in “Psychoneuroendocrinology” Blocking CYP17A1 enzyme may help improve certain brain function issues related to dopamine.
24 citations
,
July 2005 in “Journal of the American Academy of Dermatology” A woman's eyelashes grew thicker and longer after taking topiramate, but returned to normal when she stopped the medication.
26 citations
,
December 2022 in “Future Journal of Pharmaceutical Sciences” Invasomes with natural terpenes can improve drug delivery through the skin.
January 2005 in “Journal of Clinical Urology” Taking finasteride for at least 3 months before TURP reduces blood loss.
January 2025 in “The Pharma Innovation” Nanospanlastic vesicles can improve glaucoma treatment by enhancing drug delivery to the eye.
9 citations
,
October 2014 Vitamin D receptor helps prevent skin tumors.
14 citations
,
January 2020 in “Biomaterials Science” Created microspheres show potential for safe and effective use in prostate artery embolization.
April 2011 in “Cancer Research” 20(S)-Protopanaxadiol-aglycone may help prevent and treat prostate cancer by reducing androgen receptor activity.
10 citations
,
November 2017 in “Letters in drug design & discovery” Researchers identified promising inhibitors for the BRD4 protein, including finasteride and amentoflavone.
January 2018 in “Urologe A” Botulinum neurotoxin injections into the pelvic muscles successfully prevented priapism relapse for over six months.
January 2025 in “Plastic Surgery and Reconstructive Medicine” Plasmatherapy improves immune status in vitiligo patients, especially those with segmental vitiligo.
August 2021 in “The Journal of Physiology” NKCC1 transporters help control neuron excitability and inhibition.
7 citations
,
October 2019 in “Clinical, Cosmetic and Investigational Dermatology” Certain gene variations in the Vitamin D receptor may increase the risk of chronic hair loss.
25 citations
,
June 2017 in “Neuropharmacology” Increasing TSPO in the brain reduces anxiety and depression.
August 1994 in “Drugs & Therapy Perspectives” The document concludes that H2-antagonists and proton pump inhibitors are highly effective for ulcers, eradicating Helicobacter pylori is important to prevent recurrence, and misoprostol helps with NSAID-related ulcers.
24 citations
,
December 2013 in “Archives of Dermatological Research” May 2018 in “KU ScholarWorks (The University of Kansas)” Targeting 5α-reductase type 1 may help manage Tourette-like symptoms.
November 2023 in “Magna Scientia Advanced Research and Reviews” Trazodone might help reverse post finasteride syndrome.
September 2006 in “Aktuelle Urologie” Combination drug therapies are more effective for high-risk BPS patients but have more side effects and costs.
1 citations
,
December 2018 in “Journal of genetic medicine” A small change in the TRPS1 gene leads to a less severe form of a syndrome affecting hair, nose, and finger development.
March 2025 in “American Journal of Medical Genetics Part A” A rare genetic variant linked to skin cysts was found in blood DNA, suggesting its role in cyst formation.
October 2015 in “Journal of the East Asian Society of Dietary Life” Curcuma longa L. may help reduce prostate inflammation.
8 citations
,
April 2004 in “The Journal of Urology” Doxazosin and finasteride negatively affect sexual function in men with BPH.
1 citations
,
November 2024 in “Blood” PI3Kδ inhibition may effectively treat cutaneous chronic graft-versus-host disease.
March 2024 in “Cleveland Clinic journal of medicine” Alpha-blockers and 5-alpha reductase inhibitors are main treatments for BPH, with new support for phosphodiesterase-5 inhibitors and beta-3 agonists.
19 citations
,
March 2010 in “Steroids” Certain progesterone derivatives can inhibit enzymes and reduce androgenic activity, potentially affecting prostate growth.
22 citations
,
March 2017 in “Transplant Infectious Disease” Leflunomide successfully treated a rare skin condition in a liver transplant patient.
July 2023 in “Journal of Clinical Medicine” Tirzepatide might help manage PCOS in obese patients but needs more research to confirm safety and effectiveness.
1 citations
,
May 2022 in “European Journal of Dermatology” Longer treatment with vismodegib lowers relapse risk in basal cell carcinoma.